Dacomitinib for the Treatment of EGFR-mutated Advanced Non-small Cell Lung Cancer:A Rapid Health Technology Assessment
Objective:To evaluate the efficacy,safety and economy of Dacomitinib in the treatment of advanced non-small cell lung cancer with EGFR mutation,and to provide evidence-based evidence for clinical drug selection.Methods:Rapid Health Technology As-sessment(RHTA)was used.Chinese and English databases such as PubMed,Embase,the Cochrane Library,CNKI,Wanfang,China Biomedicine Database were searched by computer.Literature was screened independently by two reviewers according to inclusion and ex-clusion criteria,data were extracted,and qualitative analysis and rapid health technology assessment were conducted.Results:A total of 16 literatures were selected and included,including 8 meta-analyses and 8 economic studies.In the treatment of patients with advanced NSCLC with EGFR mutations,overall survival(OS)and progression-free survival(PFS)were significantly better in the ducatinib group than in the gefitinib,erotinib,ecotinib,afatinib and standard chemotherapy groups.It has also been shown to have a higher objective re-sponse rate(ORR)compared to chemotherapy.Compared with first-generation EGFR-TKIs,it was also shown to significantly improve treatment failure time(TTF).In terms of safety,Dacomitinib is more likely to cause rash,diarrhea,and stomatitis than chemotherapy and other EGFR-TKTs.The economic results are controversial,but in China,Dacomitinib showed a cost-effectiveness advantage com-pared with gefitinib after entering medical insurance,and the probability of economic advantage was 83.04％.Conclusions:Dacomitinib has good efficacy in the treatment of advanced NSCLC with EGFR mutation,but has no obvious advantage in terms of safety,and the eco-nomic results are controversial.
DacomitinibNon-small cell lung cancerEffectivenessSafetyEconomyRapid health technology assessment
万方数据
维普
